Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021


HOLON, Israel, Oct. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

As part of the update, management will also discuss Compugen's data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 10-14, 2021.  The eposters will be available on Friday November 12, 2021.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally.  The call and slides will be available via live webcast through Compugen's website, located at the following link

Following the live webcast, the slides and a replay will be available on the Company's website.

About Compugen 

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combinations.  COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination.  Partnered programs include bapotulimab, a first-in-class therapeutic antibody in Phase 1 development targeting ILDR2 licensed to Bayer under a research and discovery collaboration and license agreement, and AZD2936, a TIGIT/PD-1 bispecific in Phase 1 development derived from COM902 through a license agreement with AstraZeneca for the development of bispecific and multi-specific antibodies.  Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets.  Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.  For additional information, please visit Compugen's corporate website at www.cgen.com. 

Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: [email protected]
Tel: +1 (628) 241-0071

SOURCE Compugen Ltd.


These press releases may also interest you

at 20:25
AHF Praises Colombia for Putting Lives Before Pharma Greed
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC Deputy Registrar, Kathy Lauriente, honoured with Distinguished Service Award from Thompson Rivers University (TRU)
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT Expands to Meet the Growing Need for Self-Harm, Suicidal Thoughts, and Depression Therapy.
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
Notice - NOVA TECH LTD and CYNTHIA PETION, File No. 2023-20
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated Announces Increased First Quarter Dividend
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

More news about Health...


News published on and distributed by: